WO1988007361A1 - Combination of minoxidil and an anti-inflammatory agent for treating patterned alopecia - Google Patents
Combination of minoxidil and an anti-inflammatory agent for treating patterned alopecia Download PDFInfo
- Publication number
- WO1988007361A1 WO1988007361A1 PCT/US1988/000870 US8800870W WO8807361A1 WO 1988007361 A1 WO1988007361 A1 WO 1988007361A1 US 8800870 W US8800870 W US 8800870W WO 8807361 A1 WO8807361 A1 WO 8807361A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- minoxidil
- alopecia
- hair
- topically
- inflammatory agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Definitions
- the present invention relates to methods, and compositions fo treating human patterned alopecia, also called androgenic alopeci involving the use of minoxidil (or related compounds) and anti- inflammatory agents.
- Terminal hairs are coarse, pigmented, long hairs in which the bulb of the follicle is situated deep in the skin, usually in the subcutaneous tissue.
- Vellus hairs are fine, thin, non-pigmented short hairs whose bulbs are located superficially in the upper dermis.
- follicles which produce terminal hairs are gradually converted to vellus ones through a miniaturization process. Along with this progressive involution there inevitably occurs changes in the proportion of hairs in the various phases of the hair cycle.
- All follicles pass through a life cycle that includes three phases, namely, (1) anagen (2) catagen and (3) telogen.
- the anagen phase is the period of active hair growth and, on the scalp generally lasts from 3-6 years.
- Catagen is a short transitional phase when the follicle contracts in preparation for a resting period. It lasts a couple of weeks.
- telogen the follicle is in a resting phase where all growth ceases and the hair becomes short "club'* hairs. When a new cycle begins, the club hair is shed. Telogen scalp hairs are relatively short-lived, about three to four months.
- Patterned baldness is sometimes called androgenic alopecia because male hormones are necessary for its development. It does not occur before adolescence, nor in castrates. Attempts to prevent alopecia by hormonal treatments by using anti-androgens or female hormones have failed. A hereditary component is also recognized since patterned alopecia runs in families. Despite intensive investigation, the mechanism whereby terminal follicles convert to vellus ones is unknown.
- Drugs offer a more rational approach - though for the most part have been designed to interfere with drug metabolism. The results have been poor to date. In Europe, a schedule of estrogens and anti- androgens have been administered orally to balding females with inconsistent results and with obvious limitations.
- the androgenic hormone testosterone has been shown to stimulate hair growth when injected into the beard and pubic regions of adult females. Also, topical application to the armpit causes increased hair growth in aged persons. Nonetheless, topical application of testosterone has not been able to grow hair in balding individuals. Indeed, high doses of oral testosterone can induce patterned alope ⁇ cia.
- Minoxidil is a well-known pharmaceutical agent marketed by The Upjohn Company in the form of LONITEN® Tablets for the treatment of hypertension. Numerous investigators have demonstrated that it can stimulate visible hair growth in a majority of balding subjects. The structure and use of this compound is described in U.S. Patents 4,139,619 and 4,596,812. This compound has varying degrees of efficacy for moderating androge ⁇ nic alopecia, depending on the degree of baldness, its duration, the age of the patient and, of course, on the concentration of the drug in an appropriate vehicle.
- the present invention provides a novel, non-obvious and effec- tive treatment for patterned male and female alopecia.
- U.S. Patent 4,596,812 discloses the use of minoxidil, 6-amino- l,2-dihydro-l-hydroxy-2-imino-4-piperidinopyrimidine, as a thera ⁇ Promotionic agent to treat alopecia and arrest and reverse male pattern alopecia.
- U.S. Patent 4,139,619 discloses the use of minoxidil and related 6-amino-4-(subs i uted amino)-1,2-dihydro-1-hydroxy-2-imino- pyrimidines as a means for (a) increasing the rate of growth of terminal hair, and. (b) converting vellus hair to growth as terminal hair.
- the use of retinoids alone or in combination with minoxidil and related substituted pyrimidines to increase hair growth is disclosed in PCT publication numbers US85/04577, PCT US83/02558 and PCT US82/02833.
- minoxidil sulfate (2,6, -diamino-4-(1-piperidinyl)-1- (sulfooxy)-pyrimidinium hydroxide, inner salt) as a therapeutic agent to stimulate hair growth is disclosed in PCT Application US86/00073 published 31 July 1986.
- Topical antiinflammatory agents such as hydrocortisone
- topical minoxidil formulations containing, e.g., amino acids, bactericides, antiinflam- matory agents, adrenal hormones, antihistaminics, vitamin E derivatives, estrogens, and capillary vessel dilators may be prepared. No formulation containing minoxidil and the antiinflammatory agents described herein is disclosed or suggested.
- the present invention particularly provides: (1) a method of treating humans for patterned alopecia which comprises the concomitant administration to a human susceptible to said alopecia:
- a topical pharmaceutical composition for the treatment of alopecia consisting of an amount effective to treat alopecia of minoxidil and an anti-inflammatory compound in a vehicle suitable for topical application; and (3) the method in (1) wherein the anti-inflammatory agent is topically applied to the scalp.
- composition simultaneous or sequential administration of the two agents. These can be administered in any order, or can be administered together in one topical composition.
- minoxidil is meant the 2,4-pyrimidinediamine, 6-(l-piper- dinyl)-3-oxide, and analogs and salts thereof, as described in U.S. Patents 4,139,619 and 4,596,812, which patents are incorporated by reference herein.
- the use of topical minoxidil compositions in the treatment and prevention of baldness is well known to an ordinarily skilled physician or dermatologist.
- this use is set forth in U.S. Patents 4,139,619 and 4,596,812, expressly incorporated by reference herein. Similar methods can be used for the instant invention.
- anti-inflammatory agent any agent known to reduce inflammation by oral or topical administration and includes both steroidal (e.g. corticosteroids) and non-steroidal (e.g. ibuprofen and its derivatives) compounds. Steroidal compounds are used in a concentration of 0.5 to 2.5% and non-steroidals are used in a range of 1 to 5%.
- Such anti-inflammatory agents are well known to a physician of ordinary skill. See. e.g., Medical Pharmacology, pp. 331-343 9th Edition (1978). These agents may be orally or topically administered.
- simultaneous topical application of minoxidil and the anti-inflammatory agent (undertaken in a combined composition), may be preferred. However, in cases of severe inflammation, oral administration of the anti-inflammatory agent concomitant with topically administered minoxidil may be preferred.
- the present inventor has discovered that there is a chronic inflammatory process, subtending to the hair bulbs, in patterned alopecia, leading to eventual scarring of the lower follicle, making regrowth impossible.
- the present invention solves this problem by suppressing sub-bulbar infla ⁇ mation, thus allowing for regrowth.
- this invention relates to the method for treating androge ⁇ nic alopecia, both male and female, using a topical application of a pharmaceutical composition containing minoxidil and an anti- inflammatory compound.
- a pharmaceutical composition containing minoxidil and an anti- inflammatory compound An ordinary skilled physician or dermatologist can readily identify those humans susceptible to patterned alopecia who are in need of such treatment.
- the percentage by weight of the compound of the minoxidil herein utilized typically ranges from about 0.1% to about 10.0% of the preparation, preferably from about 1% to about 5% and in these preparations the carrier or vehicle constitutes a major amount of the preparation.
- compositions encompassed by this invention include formula- tions adapted for topical application to the human scalp.
- Conven ⁇ tional pharmaceutical preparations for this purpose include oint ⁇ ments, lotions, pastes, jellies, gels, mousses, sprays, foams, aerosols, and the like.
- the term "ointment” embraces formulations which include creams which are either oil-in-water or water-in-oil emulsions.
- the compounds may also be fo ⁇ rulated into liposomal preparations or lipid emulsions or dissolved in conventional solvents such as alcohol, propanol, and the like.
- the pharmaceutical preparations of the subject invention are applied on a regular basis, with or without occlusion, for a period of time sufficient to effect hair growth.
- Occlusion of the prepar ⁇ ation may be obtained by any conventional neans such as bandages, plastic coverings, shower caps swimming caps, etc.
- the percentage of active ingredients as well as frequency of application may be varied as necessary or desirable to achieve the desired results.
- DESCRIPTION OF THE PREFERRED EMBODIMENT The present invention is seen more by fully the examples given below.
- the combination formulation stimulated hair growth in these subjects within three months. Most of the subjects volunteered comments of surprise that enhancement could be seen as early as two months. These results were compared with the results of a study at the same clinic of 50 patients using 3% minoxidil alone. In the opinion of the investigator, hair growth was seen sooner and on a greater proportion of patients in the group treated with the combination of minoxidil and an antiinflammatory agent.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This invention relates to the method for treating human baldness, including the form of alopecia commonly known as ''male pattern baldness'', which comprises regular topical application to the affected areas of the human scalp of minoxidil and an anti-inflammatory agent.
Description
COMBI ATION OF MINOXIDIL AND AN ANTI-INFLAMMATORY AGENT FOR TREATING PATTERNED ALOPECIA BACKGROUND The present invention relates to methods, and compositions fo treating human patterned alopecia, also called androgenic alopeci involving the use of minoxidil (or related compounds) and anti- inflammatory agents.
Dermatologists recognize many different types of hair loss, the most common by far being "androgenic alopecia" wherein human males begin losing scalp hair at the temples and on the crown of the head in early adult life. This type of hair loss is more common and more severe in males, hence its common name "male pattern baldness". However, similar patterned baldness occurs in women, though it progresses more slowly and does not reach the end stage of complete denudation. An effective treatment for these and related conditions has long been sought.
There are two types of hair follicles which produce either "terminal hairs" or "vellus hairs". Terminal hairs are coarse, pigmented, long hairs in which the bulb of the follicle is situated deep in the skin, usually in the subcutaneous tissue. Vellus hairs, on the other hand, are fine, thin, non-pigmented short hairs whose bulbs are located superficially in the upper dermis. In patterned alopecia, follicles which produce terminal hairs are gradually converted to vellus ones through a miniaturization process. Along with this progressive involution there inevitably occurs changes in the proportion of hairs in the various phases of the hair cycle. All follicles pass through a life cycle that includes three phases, namely, (1) anagen (2) catagen and (3) telogen. The anagen phase is the period of active hair growth and, on the scalp generally lasts from 3-6 years. Catagen is a short transitional phase when the follicle contracts in preparation for a resting period. It lasts a couple of weeks. In telogen, the follicle is in a resting phase where all growth ceases and the hair becomes short "club'* hairs. When a new cycle begins, the club hair is shed. Telogen scalp hairs are relatively short-lived, about three to four months.
Normally, approximately 90% of scalp hairs are in the anagen phase, less than 1% in catagen and the remainder in telogen. With the onset of patterned baldness, a successively greater proportion of
hairs are in the telogen phase, with correspondingly fewer .in the active growth anagen phase.
Additionally, there may be some actual loss of hair follicles but this is limited to the last final phase. For the most part, the visible diminution in the bulk of hair is due to the miniaturization of the follicles. In completely bald areas, all the follicles are in the vellus phase producing ugly fine, short, non-pigmented hairs which are cosmetically useless. It may take 20 to 30 years for the distinctly anagen follicles on the crown to become transformed into a uniform population of vellus follicles.
Patterned baldness is sometimes called androgenic alopecia because male hormones are necessary for its development. It does not occur before adolescence, nor in castrates. Attempts to prevent alopecia by hormonal treatments by using anti-androgens or female hormones have failed. A hereditary component is also recognized since patterned alopecia runs in families. Despite intensive investigation, the mechanism whereby terminal follicles convert to vellus ones is unknown.
At the present time, one effective treatment for patterned alopecia is hair transplantation. Plugs of hair-bearing skin from the back of the scalp are transplanted into the bald areas. The procedure is costly and painful. Hundreds of plugs must be trans¬ planted to create .an appearance of hairiness. It is impossible to obtain anything near the original density of terminal hair. Many other approaches for creating or reversing patterned alopecia have been tried including ultra-violet radiation, massage, chemical irritation and innumerable natural products and herbs. None of these has been generally accepted as effective.
Drugs offer a more rational approach - though for the most part have been designed to interfere with drug metabolism. The results have been poor to date. In Europe, a schedule of estrogens and anti- androgens have been administered orally to balding females with inconsistent results and with obvious limitations.
The androgenic hormone testosterone has been shown to stimulate hair growth when injected into the beard and pubic regions of adult females. Also, topical application to the armpit causes increased hair growth in aged persons. Nonetheless, topical application of testosterone has not been able to grow hair in balding individuals.
Indeed, high doses of oral testosterone can induce patterned alope¬ cia.
The topical application of minoxidil is currently the most effective therapy for patterned alopecia. Minoxidil is a well-known pharmaceutical agent marketed by The Upjohn Company in the form of LONITEN® Tablets for the treatment of hypertension. Numerous investigators have demonstrated that it can stimulate visible hair growth in a majority of balding subjects. The structure and use of this compound is described in U.S. Patents 4,139,619 and 4,596,812. This compound has varying degrees of efficacy for moderating androge¬ nic alopecia, depending on the degree of baldness, its duration, the age of the patient and, of course, on the concentration of the drug in an appropriate vehicle.
The present invention provides a novel, non-obvious and effec- tive treatment for patterned male and female alopecia.
INFORMATION DISCLOSURE U.S. Patent 4,596,812 discloses the use of minoxidil, 6-amino- l,2-dihydro-l-hydroxy-2-imino-4-piperidinopyrimidine, as a thera¬ peutic agent to treat alopecia and arrest and reverse male pattern alopecia. U.S. Patent 4,139,619 discloses the use of minoxidil and related 6-amino-4-(subs i uted amino)-1,2-dihydro-1-hydroxy-2-imino- pyrimidines as a means for (a) increasing the rate of growth of terminal hair, and. (b) converting vellus hair to growth as terminal hair. The use of retinoids alone or in combination with minoxidil and related substituted pyrimidines to increase hair growth is disclosed in PCT publication numbers US85/04577, PCT US83/02558 and PCT US82/02833.
The use of minoxidil sulfate (2,6, -diamino-4-(1-piperidinyl)-1- (sulfooxy)-pyrimidinium hydroxide, inner salt) as a therapeutic agent to stimulate hair growth is disclosed in PCT Application US86/00073 published 31 July 1986.
Topical antiinflammatory agents, such as hydrocortisone, are known, see, e.g., The Merck Index, Tenth Edition, 4689 (1983). Japanese patent Kokai 61-260010 states that topical minoxidil formulations containing, e.g., amino acids, bactericides, antiinflam- matory agents, adrenal hormones, antihistaminics, vitamin E derivatives, estrogens, and capillary vessel dilators may be
prepared. No formulation containing minoxidil and the antiinflammatory agents described herein is disclosed or suggested.
SUMMARY OF THE INVENTION The present invention particularly provides: (1) a method of treating humans for patterned alopecia which comprises the concomitant administration to a human susceptible to said alopecia:
(a) an effective amount of minoxidil, administered topically to the scalp; and (b) an anti-inflammatory compound, administered topically or orally;
(2) a topical pharmaceutical composition for the treatment of alopecia consisting of an amount effective to treat alopecia of minoxidil and an anti-inflammatory compound in a vehicle suitable for topical application; and (3) the method in (1) wherein the anti-inflammatory agent is topically applied to the scalp.
By "concomitant administration" or "combination" is meant simultaneous or sequential administration of the two agents. These can be administered in any order, or can be administered together in one topical composition.
By minoxidil is meant the 2,4-pyrimidinediamine, 6-(l-piper- dinyl)-3-oxide, and analogs and salts thereof, as described in U.S. Patents 4,139,619 and 4,596,812, which patents are incorporated by reference herein. The use of topical minoxidil compositions in the treatment and prevention of baldness is well known to an ordinarily skilled physician or dermatologist. In addition, this use is set forth in U.S. Patents 4,139,619 and 4,596,812, expressly incorporated by reference herein. Similar methods can be used for the instant invention.
By anti-inflammatory agent is meant any agent known to reduce inflammation by oral or topical administration and includes both steroidal (e.g. corticosteroids) and non-steroidal (e.g. ibuprofen and its derivatives) compounds. Steroidal compounds are used in a concentration of 0.5 to 2.5% and non-steroidals are used in a range of 1 to 5%. Such anti-inflammatory agents are well known to a physician of ordinary skill. See. e.g., Medical Pharmacology, pp. 331-343 9th Edition (1978). These agents may be orally or topically
administered. For ease of administration, simultaneous topical application of minoxidil and the anti-inflammatory agent (undertaken in a combined composition), may be preferred. However, in cases of severe inflammation, oral administration of the anti-inflammatory agent concomitant with topically administered minoxidil may be preferred.
Surprisingly, the present inventor has discovered that there is a chronic inflammatory process, subtending to the hair bulbs, in patterned alopecia, leading to eventual scarring of the lower follicle, making regrowth impossible. The present invention solves this problem by suppressing sub-bulbar inflaπmation, thus allowing for regrowth.
Thus, this invention relates to the method for treating androge¬ nic alopecia, both male and female, using a topical application of a pharmaceutical composition containing minoxidil and an anti- inflammatory compound. An ordinary skilled physician or dermatologist can readily identify those humans susceptible to patterned alopecia who are in need of such treatment.
The percentage by weight of the compound of the minoxidil herein utilized typically ranges from about 0.1% to about 10.0% of the preparation, preferably from about 1% to about 5% and in these preparations the carrier or vehicle constitutes a major amount of the preparation.
The compositions encompassed by this invention include formula- tions adapted for topical application to the human scalp. Conven¬ tional pharmaceutical preparations for this purpose include oint¬ ments, lotions, pastes, jellies, gels, mousses, sprays, foams, aerosols, and the like. The term "ointment" embraces formulations which include creams which are either oil-in-water or water-in-oil emulsions. The compounds may also be foπrulated into liposomal preparations or lipid emulsions or dissolved in conventional solvents such as alcohol, propanol, and the like.
The pharmaceutical preparations of the subject invention are applied on a regular basis, with or without occlusion, for a period of time sufficient to effect hair growth. Occlusion of the prepar¬ ation may be obtained by any conventional neans such as bandages, plastic coverings, shower caps swimming caps, etc. The percentage of active ingredients as well as frequency of application may be varied
as necessary or desirable to achieve the desired results. DESCRIPTION OF THE PREFERRED EMBODIMENT The present invention is seen more by fully the examples given below. Example 1
Fifteen males with early alopecia were treated with a combination of 2% minoxidil and 1% hydrocortisone in a hydroalcoholic vehicle. The subjects were shampooed weekly and hairs were counted after filtration. Fewer hairs were observed to be shed as treatment progressed. Hair regrowth has been substantially better than with minoxidil alone in comparable cases. The longest period of treatment is 6 months. Hair loss has virtually stopped in all subjects. Example 2
Twenty-six young-adult, balding white males were treated for at ' least five months with a hydroalcoholic solution containing: (1) 3% minoxidil; and (2) 2.5% hydrocortisone. These subjects were in an early stage of baldness, not exceeding 2 inches in diameter over the vertex.
The combination formulation stimulated hair growth in these subjects within three months. Most of the subjects volunteered comments of surprise that enhancement could be seen as early as two months. These results were compared with the results of a study at the same clinic of 50 patients using 3% minoxidil alone. In the opinion of the investigator, hair growth was seen sooner and on a greater proportion of patients in the group treated with the combination of minoxidil and an antiinflammatory agent.
Claims
1. A method of treating humans for patterned alopecia which comprises the concomitant administration to a human susceptible to said alopecia an effective amount of: (a) minoxidil, administered topically; and
(b) an anti-inflammatory compound, administered topically or orally.
2. A topical pharmaceutical composition for the treatment of alopecia consisting of an amount effective to treat alopecia of minoxidil and an anti-inflammatory compound in a vehicle adapted for topical application.
3. A method of Claim 1, wherein the anti-inflammatory agent is topically applied to the scalp.
4. A method of Claim 3, wherein minoxidil is applied at a concentration of 2% and hydrocortisone is applied topically at a concentration of 1%.
5. A composition of Claim 1, containing 2% minoxidil and 1% hydrocortisone.
6. A method of Claim 3, wherein minoxidil is applied topically at a concentration of 3% and hydrocortisone is topically applied at a concentration of 2.5%.
7. A composition of Claim 1, containing 3% minoxidil and 2.5% hydrocortisone.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP88903106A EP0357630B1 (en) | 1987-03-30 | 1988-03-23 | Combination of minoxidil and an anti-inflammatory agent for treating patterned alopecia |
DE3853884T DE3853884T2 (en) | 1987-03-30 | 1988-03-23 | COMBINATION OF MINOXIDIL AND AN ANTI-INFLAMMATORY SUBSTANCE FOR THE TREATMENT OF ALOPECIA. |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3236287A | 1987-03-30 | 1987-03-30 | |
US032,362 | 1987-03-30 | ||
US5567487A | 1987-05-29 | 1987-05-29 | |
US055,674 | 1987-05-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1988007361A1 true WO1988007361A1 (en) | 1988-10-06 |
Family
ID=26708326
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1988/000870 WO1988007361A1 (en) | 1987-03-30 | 1988-03-23 | Combination of minoxidil and an anti-inflammatory agent for treating patterned alopecia |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0357630B1 (en) |
JP (1) | JPH02502818A (en) |
AT (1) | ATE122873T1 (en) |
AU (1) | AU1542288A (en) |
DE (1) | DE3853884T2 (en) |
WO (1) | WO1988007361A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0321951A1 (en) * | 1987-12-22 | 1989-06-28 | L'oreal | Combination of pyrimidine derivatives and fluorized steroidal anti-inflammatory agents to induce and stimulate the hair growth and to reduce hair loss |
EP0321952A1 (en) * | 1987-12-22 | 1989-06-28 | L'oreal | Association of pyrimidine derivatives and non-steroidal anti-inflammatory agents to induce and stimulate the hair growth and to reduce the hair loss |
EP0336812A2 (en) * | 1988-03-31 | 1989-10-11 | L'oreal | Association of pyrimidine derivatives and urea and/or allantoin derivatives to induce and stimulate hair growth and to reduce hair loss |
WO1990006100A1 (en) * | 1988-12-02 | 1990-06-14 | The Upjohn Company | Minoxidil and vasoconstrictor compositions for treating alopecia |
WO1992002225A1 (en) * | 1990-08-10 | 1992-02-20 | The Upjohn Company | STIMULATION OF HAIR GROWTH WITH POTASSIUM CHANNEL OPENERS AND 5α-REDUCTASE INHIBITORS |
WO2006051287A1 (en) * | 2004-11-10 | 2006-05-18 | Arrow International Limited | Composition and method for treatment of alopecia areata |
ITMI20081401A1 (en) * | 2008-07-29 | 2010-01-30 | Gaetano Agostinacchio | COMPOSITION INCLUDING AN ASSOCIATION OF ACTIVE PRINCIPLES FOR USE IN THE TOPIC TREATMENT OF CALVIZIE |
EP2782582A4 (en) * | 2011-11-25 | 2016-09-28 | Adrianna Janell Jackson | Oil compositions and methods for increasing hair growth and/or preventing hair loss |
CN110755286A (en) * | 2019-11-18 | 2020-02-07 | 童婧 | Hairline filling composition helpful for hair growth |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69637984D1 (en) * | 1995-12-28 | 2009-09-17 | Panasonic Corp | Optical waveguide, optical wavelength conversion device and method of making the same |
JP2007008965A (en) * | 2006-10-23 | 2007-01-18 | Pola Chem Ind Inc | Hair growing agent |
IT201700055361A1 (en) * | 2017-05-22 | 2018-11-22 | Mdm Ind S R L | Method for the prevention and treatment of hair loss. |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4141976A (en) * | 1976-01-05 | 1979-02-27 | The Regents Of The University Of Michigan | Process for alleviating proliferative skin diseases |
EP0220118A2 (en) * | 1985-10-11 | 1987-04-29 | Centre International De Recherches Dermatologiques Galderma - Cird Galderma | Bicyclic naphthalenic derivatives, process for their preparation and their use in human and veterinary medicine and cosmetics |
-
1988
- 1988-03-23 WO PCT/US1988/000870 patent/WO1988007361A1/en active IP Right Grant
- 1988-03-23 DE DE3853884T patent/DE3853884T2/en not_active Expired - Fee Related
- 1988-03-23 JP JP63501428A patent/JPH02502818A/en active Pending
- 1988-03-23 EP EP88903106A patent/EP0357630B1/en not_active Expired - Lifetime
- 1988-03-23 AT AT88903106T patent/ATE122873T1/en not_active IP Right Cessation
- 1988-03-23 AU AU15422/88A patent/AU1542288A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4141976A (en) * | 1976-01-05 | 1979-02-27 | The Regents Of The University Of Michigan | Process for alleviating proliferative skin diseases |
EP0220118A2 (en) * | 1985-10-11 | 1987-04-29 | Centre International De Recherches Dermatologiques Galderma - Cird Galderma | Bicyclic naphthalenic derivatives, process for their preparation and their use in human and veterinary medicine and cosmetics |
Non-Patent Citations (3)
Title |
---|
Patent Abstracts of Japan, vol. 11, no. 3 (C-395)(2450), 7 January 1987; & JP-A-61183209 (LION CORP.) 15 August 1986 * |
Patent Abstracts of Japan, volume 11, no. 115 (C-415)(2562), 10 April 1987; & JP-A- 61260010 (YAMAGUCHI YAKUHIN SHOKAI K.K.) 18 November 1986 * |
S.T.N., File Supplier, (Karlsruhe, DE), & Chemical Abstracts, vol. 106, 5 June 1987, abstract no. 201544m & JP,A, 6233111 (MURAI, TADAYOSHI) 13 February 1987 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5643898A (en) * | 1987-12-22 | 1997-07-01 | L'oreal | Combination of derivatives of pyrimidine and of hydrocortisone for inducing and stimulating the growth of hair and reducing its loss |
EP0321950A1 (en) * | 1987-12-22 | 1989-06-28 | L'oreal | Combination of pyrimidine derivatives and hydrocortisone to induce and stimulate the hair growth and to reduce hair loss |
EP0321952A1 (en) * | 1987-12-22 | 1989-06-28 | L'oreal | Association of pyrimidine derivatives and non-steroidal anti-inflammatory agents to induce and stimulate the hair growth and to reduce the hair loss |
EP0321951A1 (en) * | 1987-12-22 | 1989-06-28 | L'oreal | Combination of pyrimidine derivatives and fluorized steroidal anti-inflammatory agents to induce and stimulate the hair growth and to reduce hair loss |
EP0336812A2 (en) * | 1988-03-31 | 1989-10-11 | L'oreal | Association of pyrimidine derivatives and urea and/or allantoin derivatives to induce and stimulate hair growth and to reduce hair loss |
EP0336812A3 (en) * | 1988-03-31 | 1989-10-25 | L'oreal | Association of pyrimidine derivatives and urea and/or allantoin derivatives to induce and stimulate hair growth and to reduce hair loss |
US5443823A (en) * | 1988-03-31 | 1995-08-22 | L'oreal | Combination of pyrimidine derivatives and of salicylic acid derivatives for inducing and stimulating the growth of hair and reducing its loss |
WO1990006100A1 (en) * | 1988-12-02 | 1990-06-14 | The Upjohn Company | Minoxidil and vasoconstrictor compositions for treating alopecia |
WO1992002225A1 (en) * | 1990-08-10 | 1992-02-20 | The Upjohn Company | STIMULATION OF HAIR GROWTH WITH POTASSIUM CHANNEL OPENERS AND 5α-REDUCTASE INHIBITORS |
WO2006051287A1 (en) * | 2004-11-10 | 2006-05-18 | Arrow International Limited | Composition and method for treatment of alopecia areata |
ITMI20081401A1 (en) * | 2008-07-29 | 2010-01-30 | Gaetano Agostinacchio | COMPOSITION INCLUDING AN ASSOCIATION OF ACTIVE PRINCIPLES FOR USE IN THE TOPIC TREATMENT OF CALVIZIE |
WO2010013110A2 (en) * | 2008-07-29 | 2010-02-04 | Gaetano Agostinacchio | Composition comprising an association of active principles for use in the topical treatment of baldness |
WO2010013110A3 (en) * | 2008-07-29 | 2010-03-25 | Gaetano Agostinacchio | Composition comprising estrone and hydrocortisone for use in the topical treatment of baldness |
EP2782582A4 (en) * | 2011-11-25 | 2016-09-28 | Adrianna Janell Jackson | Oil compositions and methods for increasing hair growth and/or preventing hair loss |
CN110755286A (en) * | 2019-11-18 | 2020-02-07 | 童婧 | Hairline filling composition helpful for hair growth |
Also Published As
Publication number | Publication date |
---|---|
ATE122873T1 (en) | 1995-06-15 |
DE3853884T2 (en) | 1995-11-23 |
EP0357630A1 (en) | 1990-03-14 |
DE3853884D1 (en) | 1995-06-29 |
AU1542288A (en) | 1988-11-02 |
EP0357630B1 (en) | 1995-05-24 |
JPH02502818A (en) | 1990-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4596812A (en) | Methods and solutions for treating male pattern alopecia | |
US5026691A (en) | Combination of minoxidil and an antiinflammatory agent for treating patterned alopecia | |
WO1988007361A1 (en) | Combination of minoxidil and an anti-inflammatory agent for treating patterned alopecia | |
EP2498784A2 (en) | Compositions for enhancing hair growth | |
US20230363999A1 (en) | Composition for treating hair loss or promoting hair growth comprising growth factor | |
US5643942A (en) | Methods, composition and solutions for treating alopecia | |
EP0659080B1 (en) | Method for the treatment of hair loss | |
JPH11269043A (en) | Cosmetic for scalp and hair | |
WO2000048559A2 (en) | Composition for promoting hair growth comprising derivatives of vitamins and dmso | |
JPH11269042A (en) | Cosmetic for scalp and hair | |
Fenton et al. | Alopecia areata treated with topical minoxidil | |
JPH0853327A (en) | Hair tonic composed of allantoin or its derivative | |
JPH11302133A (en) | Cosmetic for scalp and hair | |
JPH1017439A (en) | Hair growing and restoring agent | |
JP2546813B2 (en) | Hair nourishing cosmetics | |
JPH11302131A (en) | Cosmetic for scalp and hair | |
JPH0676296B2 (en) | Nourishing skin cosmetics | |
JPH11255621A (en) | Cosmetic for scalp and hair | |
JPH11302128A (en) | Cosmetic for scalp and hair | |
JPH11263714A (en) | Cosmetic for scalp and hair of head | |
JPH0640858A (en) | Hair tonic | |
JPH0248512A (en) | Hair tonic | |
JPH0455163B2 (en) | ||
AU8276987A (en) | Use of nicorandil to treat alopecia | |
EP0769950A1 (en) | Method and compound for the treatment of hair loss |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU DK FI JP KR NO US US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1988903106 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1988903106 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1988903106 Country of ref document: EP |